There were no initial public offerings in September
There were no follow-on offerings in September.
Company Date Shares/ Price Shares Lead, Value@
(Symbol) Filed Units (M) Range Out (M) Other UWs ($M)
Anthra Pharma- 3/11; 2.0U $5 6.9 JM $10
ceuticals Inc.* 9/25
Centaur Pharma- 6/18 4.0S $13-$15 17.8 BJV; VSI $52
ceuticals Inc.**
Lifecodes Corp.# 7/17 2.9S $10-$12 6.6 VBW; VSI; AI $29
Praecis Pharma- 8/12 3.5S $14-$16 19.2 BTAB; NBMS $49
ceuticals Inc.
Signal Pharma- 5/15 2.5S $11-$13 9.4 HQ; BRS; LB $27.5
ceuticals Inc.##
* Anthra Pharmaceuticals Inc. amended its initial public offering (IPO) prospectus on 9/25; the company is now planning to sell 2M units (each consisting of 1 share of stock and one 5-year warrant to buy 1 share of stock at $6.00) instead of 2.7M shares. It also has changed underwriters from Allen & Co. Inc. and Gruntal & Co. LLC to Janssen/Meyers Associates LP.
** Centaur Pharmaceuticals Inc.'s IPO filing actually consists of 5.6M shares; of those, the company is offering 4M and selling stockholders are offering 1.6M. This is also an international offering, with 1.68M shares being offered in the U.S. and Canada and 3.92M shares being offered in Switzerland and elsewhere outside the U.S. and Canada. The company intends to list its shares on the Swiss Stock Exchange and not on any U.S. or other exchanges.
# Lifecodes Corp. filed to sell 3.2M shares in its IPO; the company is offering 2.9M shares and selling shareholders are offering 0.3M shares. Concurrent with the completion of its IPO, Lifecodes will acquire privately held GeneScreen Inc. for $12.5M ($5M in cash and $7.5M in common stock).
## Signal Pharmaceuticals Inc.'s corporate collaborator DuPont Merck Pharmaceutical Co. will purchase $2M worth of stock in a private placement concurrent with the IPO, at the IPO price per share.
There are no follow-on offerings in registration.
Albany Molecular 7/9 2.2S $15-$17 9.5 INGB; HQ $33
Research Inc.*
Genzyme Molecular 4/28 3.0S $9-$11 13.2 PW; CC; CSFBC $27
* Albany Molecular Research Inc. postponed its IPO in early September, due to market conditions.
** Genzyme Molecular Oncology had postponed its IPO on 6/25, due to market conditions. The company withdrew the IPO on 9/21; Genzyme Corp. stated that it will distribute Genzyme Molecular Oncology shares to the former's shareholders. Genzyme Molecular Oncology shares will then begin trading on Nasdaq.
E = estimated; ND = not disclosed, reported and/or available; S = shares; U = units; W = warrants
"Date filed" indicates the date on which the company announced that it had filed a preliminary prospectus with the Securities and Exchange Commission for its offering. It is not necessarily the same date as that which is printed on the preliminary prospectus itself.
In completed offerings, the number of shares sold includes the overallotment (in full or in part) if that option has been exercised by the time this publication goes to press.
Shares outstanding refers to the number of shares outstanding after the public offering. In the case of those offerings which are still pending, it assumes that the number of shares sold in the offering will be equal to the number intended for sale as per the prospectus.
@ Values are estimated from the low-end range for IPOs.

Underwriters' Key:

AI (Advest Inc.); BRS (BancBoston Robertson Stephens); BJV (Bank J. Vontobel & Co. AG); BTAB (BT Alex. Brown Inc.); CC (Cowen & Co.); CSFBC (Credit Suisse First Boston Corp.); HQ (Hambrecht & Quist LLC); INGB (ING Baring Furman Selz LLC); JM (Janssen/Meyers Associates LP); LB (Lehman Brothers); NMBS (NationsBanc Montgomery Securities Inc.); PW (PanieWebber Inc.); VBW (Volpe Brown Whelan & Co.); VSI (Vector Securities International Inc.)